Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation

Transplantation Reviews

Volumn 27, Issue 4, 2013, Pages 117-125

  Zuber, Julien ^a,b   Le Quintrec, Moglie ^c   Morris, Heather ^d   Frémeaux Bacchi, Véronique ^e   Loirat, Chantal ^f   Legendre, Christophe ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c FOCH HOSPITAL   (France)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BELATACEPT; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT FACTOR; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMBRANE COFACTOR PROTEIN; MENINGOCOCCUS VACCINE; PLACEBO;

BRAIN DEATH; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG SAFETY; ENDOTHELIUM INJURY; FOOD AND DRUG ADMINISTRATION; GENOTYPE ENVIRONMENT INTERACTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LIVING DONOR; MENINGOCOCCOSIS; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; REPERFUSION INJURY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC;

EID: 84884821706     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.07.003     Document Type: Review

References (123)

1. Loirat C., Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003, 18:1095-1101.
2. Zuber J., Le Quintrec M., Sberro-Soussan R., Loirat C., Frémeaux-Bacchi V., Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011, 7:23-35.
3. Gruppo R.A., Rother R.P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:544-546.
4. Nurnberger J., Philipp T., Witzke O., et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:542-544.
5. Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-657. [Review].
6. Legendre C.M., LIcht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
7. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
8. Noris M., Caprioli J., Bresin E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol: CJASN 2010, 5:1844-1859. Comparative Study Research Support, Non-U.S. Gov't.
9. Fremeaux-Bacchi V., Fakhouri F., Garnier A., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clinical journal of the American Society of Nephrology: CJASN 2013, 8:554-562. [Research Support, Non-U.S. Gov't].
10. Tsai H.M. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Journal of the American Society of Nephrology: JASN 2003, 14:1072-1081. [Research Support, U.S. Gov't, P.H.S. Review].
11. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney international. Case Reports Review 1987, 32:292-308.
12. Caprioli J., Bettinaglio P., Zipfel P.F., et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001, 12:297-307.
13. Caprioli J., Castelletti F., Bucchioni S., et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003, 12:3385-3395.
14. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004, 41:e84.
15. Kavanagh D., Kemp E.J., Mayland E., et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:2150-2155.
16. Fremeaux-Bacchi V., Moulton E.A., Kavanagh D., et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006, 17:2017-2025.
17. Noris M., Brioschi S., Caprioli J., et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547.
18. Richards A., Kemp E.J., Liszewski M.K., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003, 100:12966-12971.
19. Delvaeye M., Noris M., De Vriese A., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357.
20. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007, 104:240-245.
21. Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948-4952.
22. Roumenina L.T., Jablonski M., Hue C., et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009, 114:2837-2845.
23. Abarrategui-Garrido C., Martinez-Barricarte R., Lopez-Trascasa M., de Cordoba S.R., Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
24. Dragon-Durey M.A., Blanc C., Marliot F., et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009, 46:447-450.
25. Jozsi M., Licht C., Strobel S., et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
26. Frimat M., Tabarin F., Dimitrov J.D., et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013, 122:282-292.
27. Lemaire M., Fremeaux-Bacchi V., Schaefer F., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45:531-536.
28. Bresin E., Daina E., Noris M., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1:88-99.
29. Le Quintrec M., Zuber J., Moulin B., et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-675.
30. Sellier-Leclerc A.L., Fremeaux-Bacchi V., Dragon-Durey M.A., et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007, 18:2392-2400.
31. Artz M.A., Steenbergen E.J., Hoitsma A.J., Monnens L.A., Wetzels J.F. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003, 76:821-826.
32. Kwan W.H., Hashimoto D., Paz-Artal E., et al. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest 2012, 122:2234-2238. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
33. Raedler H., Heeger P.S. Complement regulation of T-cell alloimmunity. Curr Opin Organ Transplant 2011, 16:54-60. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
34. Raedler H., Vieyra M.B., Leisman S., et al. Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant 2011, 11:1397-1406. [Research Support, N.I.H., Extramural].
35. Raedler H., Yang M., Lalli P.N., Medof M.E., Heeger P.S. Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant 2009, 9:1784-1795.
36. Bresin E., Rurali E., Caprioli J., et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475-486. [Research Support, Non-U.S. Gov't].
37. Esparza-Gordillo J., Goicoechea de Jorge E., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005, 14:703-712.
38. Fremeaux-Bacchi V., Kemp E.J., Goodship J.A., et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005 Nov, 42:852-856.
39. Fremeaux-Bacchi V., Arzouk N., Ferlicot S., Charpentier B., Snanoudj R., Durrbach A. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant 2007, 7:2047-2051.
40. Saland J.M., Ruggenenti P., Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20:940-949.
41. Venables J.P., Strain L., Routledge D., et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006, 3:e431.
42. Caprioli J., Noris M., Brioschi S., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
43. Kavanagh D., Goodship T.H. Membrane cofactor protein and factor I: mutations and transplantation. Semin Thromb Hemost 2006, 32:155-159.
44. Naesens M., Li L., Ying L., et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol: JASN 2009, 20:1839-1851. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
45. van Werkhoven M.B., Damman J., van Dijk M.C., et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant 2013, 13:875-882. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S].
46. Thurman J.M., Lucia M.S., Ljubanovic D., Holers V.M. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005, 67:524-530. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
47. Renner B., Coleman K., Goldberg R., et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 2010, 185:3086-3094. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
48. Snoeijs M.G., Vink H., Voesten N., et al. Acute ischemic injury to the renal microvasculature in human kidney transplantation. Am J Physiol Renal Physiol 2010, 299:F1134-F1140. [Research Support, Non-U.S. Gov't].
49. Zhou W., Farrar C.A., Abe K., et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000, 105:1363-1371. [Research Support, Non-U.S. Gov't].
50. Blogowski W., Dolegowska B., Salata D., Budkowska M., Domanski L., Starzynska T. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation. Clinical journal of the American Society of Nephrology: CJASN 2012, 7:1843-1851. [Research Support, Non-U.S. Gov't].
51. de Vries D.K., van der Pol P., van Anken G.E., et al. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation 2013, 95:816-820. [Research Support, Non-U.S. Gov't].
52. Koskinen A.R., Tukiainen E., Arola J., et al. Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011, 11:1885-1895. [Research Support, Non-U.S. Gov't].
53. Thurman J.M., Royer P.A., Ljubanovic D., et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. Journal of the American Society of Nephrology: JASN 2006, 17:707-715. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
54. Zheng X., Feng B., Chen G., et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 2006, 6:2099-2108.
55. Davin J.C., Strain L., Goodship T.H. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008, 23:1517-1521.
56. Olie K.H., Goodship T.H., Verlaak R., et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 2005, 45:e12-e15.
57. Al-Akash S.I., Almond P.S., Savell V.H., Gharaybeh S.I., Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011, 26:613-619. [Case Reports].
58. Printza N., Roilides E., Kotsiou M., Zafeiriou D., Hatzidimitriou V., Papachristou F. Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:143-144. [Case Reports Letter].
59. Trachtman H., Sethna C., Epstein R., D'Souza M., Rubin L.G., Ginocchio C.C. Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection. Pediatr Nephrol 2011, 26:145-146. [Case Reports Letter].
60. Murer L., Zacchello G., Bianchi D., et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000, 11:1132-1137.
61. Petrogiannis-Haliotis T., Sakoulas G., Kirby J., et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med 2001 Oct 25, 345:1250-1255.
62. Weitz M., Amon O., Bassler D., Koenigsrainer A., Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:1325-1329. [Case Reports].
63. Nester C., Stewart Z., Myers D., et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol: CJASN 2011, 6:1488-1494. [Case Reports].
64. Simmonds J., Fenton M., Dewar C., et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation 2008, 117:2657-2661.
65. Bolovan-Fritts C.A., Spector S.A. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 2008, 111:175-182.
66. Al-Massarani G., Vacher-Coponat H., Paul P., et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant 2008, 8:2360-2367.
67. Miriuka S.G., Rao V., Peterson M., et al. mTOR inhibition induces endothelial progenitor cell death. Am J Transplant 2006, 6:2069-2079.
68. Fortin M.C., Raymond M.A., Madore F., et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004, 4:946-952.
69. Liptak P., Ivanyi B. Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006, 2:398-404. [quiz following].
70. Naesens M., Kuypers D.R., Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009, 4:481-508.
71. Robson M., Cote I., Abbs I., Koffman G., Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage?. Am J Transplant 2003, 3:324-327.
72. Ruggenenti P. Post-transplant hemolytic-uremic syndrome. Kidney Int 2002, 62:1093-1104.
73. Schwimmer J., Nadasdy T.A., Spitalnik P.F., Kaplan K.L., Zand M.S. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003, 41:471-479.
74. Reynolds J.C., Agodoa L.Y., Yuan C.M., Abbott K.C. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003, 42:1058-1068.
75. Lovric S., Kielstein J.T., Kayser D., et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients-a case series. Nephrol Dial Transplant 2011, 26:3032-3038. [Case Reports Multicenter Study Research Support, Non-U.S. Gov't].
76. Ghez D., Rubio M.T., Maillard N., et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009, 88:1081-1087.
77. Rosenthal J., Pawlowska A., Bolotin E., et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer 2011, 57:142-146. [Clinical Trial Research Support, N.I.H., Extramural].
78. Le Quintrec M., Lionet A., Kamar N., et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008, 8:1694-1701.
79. Wilson C.H., Brown A.L., White S.A., Goodship T.H., Sheerin N.S., Manas D.M. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011, 92:e42-e43. [Letter].
80. Ashman N., Chapagain A., Dobbie H., Raftery M.J., Sheaff M.T., Yaqoob M.M. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009, 9:424-427.
81. Midtvedt K., Bitter J., Dorje C., Bjorneklett R., Holdaas H. Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation 2009, 87:1901-1903.
82. Meehan S.M., Kremer J., Ali F.N., et al. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol: CJASN 2011 Feb, 6:395-403.
83. Satoskar A.A., Pelletier R., Adams P., et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 2010, 10:1804-1811.
84. Noone D, Al-Matrafi J, Tinckam K, et al. Antibody Mediated Rejection Associated With Complement Factor H-Related Protein 3/1 Deficiency Successfully Treated With Eculizumab. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012 Jun 8.
85. Heinen S., Hartmann A., Lauer N., et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009, 114:2439-2447.
86. Bienaime F., Dragon-Durey M.A., Regnier C.H., et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010, 77:339-349.
87. Stegall M.D., Diwan T., Raghavaiah S., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11:2405-2413.
88. Canaud G., Bienaime F., Noel L.H., et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010, 10:2051-2060.
89. Canaud G., Kamar N., Anglicheau D., et al. Eculizumab improves post-transplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but failed to prevent chronic vascular changes. Am J Transplant 2013, in press.
90. Hadaya K., Ferrari-Lacraz S., Fumeaux D., et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011, 11:2523-2527. [Case Reports Research Support, Non-U.S. Gov't].
91. Fakhouri F., Roumenina L., Provot F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol: JASN 2010, 21:859-867. [Research Support, Non-U.S. Gov't].
92. Fakhouri F., Vercel C., Fremeaux-Bacchi V. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol: CJASN 2012, 7:2100-2106. [Research Support, Non-U.S. Gov't Review].
93. Chapin J., Eyler S., Smith R., Tsai H.M., Laurence J. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood 2013, 121:4012-4013.
94. Fang C.J., Fremeaux-Bacchi V., Liszewski M.K., et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008, 111:624-632.
95. Larrea C.F., Cofan F., Oppenheimer F., Campistol J.M., Escolar G., Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010, 89:903-904.
96. Esparza-Gordillo J., Jorge E.G., Garrido C.A., et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006, 43:1769-1775.
97. Moore I., Strain L., Pappworth I., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
98. Forbes T.A., Bradbury M.G., Goodship T.H., McKiernan P.J., Milford D.V. Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: A tertiary case series. Pediatr Transplant 2013, 17:E93-E99.
99. Loirat C., Saland J., Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012, 41:e115-e135.
100. Remuzzi G., Ruggenenti P., Codazzi D., et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002, 359:1671-1672.
101. Remuzzi G., Ruggenenti P., Colledan M., et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005, 5:1146-1150.
102. Lennon F.E., Singleton P.A. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis 2011, 1:200-213.
103. Rehm M., Bruegger D., Christ F., et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007, 116:1896-1906. [Research Support, Non-U.S. Gov't].
104. Cheong H.I., Lee B.S., Kang H.G., et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004, 19:454-458.
105. Haller W., Milford D.V., Goodship T.H., Sharif K., Mirza D.F., McKiernan P.J. Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant 2010 Sep, 10:2142-2147. [Case Reports Research Support, Non-U.S. Gov't].
106. Alachkar N., Bagnasco S.M., Montgomery R.A. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int 2012, 25:e93-e95. [Case Reports Letter].
107. Zuber J., Le Quintrec M., Krid S., et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:3337-3354. [Comparative Study Multicenter Study].
108. Le Quintrec M., Zuber J., Noel L.H., et al. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009, 9:1223-1229.
109. Davin J.C., Buter N., Groothoff J., et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009, 24:1757-1760.
110. Chatelet V., Fremeaux-Bacchi V., Lobbedez T., Ficheux M., de Ligny B.H. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009, 9:2644-2645.
111. Krid S., Roumenina L.T., Beury D., et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012, in press.
112. Zimmerhackl L.B., Hofer J., Cortina G., et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010, 362:1746-1748.
113. Xie L., Nester C.M., Reed A.I., Zhang Y., Smith R.J., Thomas C.P. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc 2012, 44:3037-3040. [Case Reports].
114. Loirat C., Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008, 12:619-629.
115. Duran C.E., Blasco M., Maduell F., Campistol J.M. Rescue therapy with eculizumab in a transient recipient with atypical haematologic-uraemic syndrome. Clin Kidney J 2012, 5:28-30.
116. Legault D, Boelkins M. Succesful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. 51st Annual meeting of the American Society of Hematology Grand Rapids, MI2009. p. 2421.
117. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. American journal of kidney diseases: the official journal of the National Kidney Foundation. [Case Reports]. 2010 Apr;55:708-11.
118. Fernandez-Ruiz M, Lopez-Medrano F, Varela-Pena P, et al. Hypocomplementemia in kidney transplant recipients: impact on the risk of infectious complications. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. [Research Support, Non-U.S. Gov't]. 2013 Mar;13:685-94.
119. Overturf G.D. Indications for the immunological evaluation of patients with meningitis. Clin Infect Dis 2003, 36:189-194.
120. Brodsky RA, de Castro III C, Schrezenmeier H, et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH). 52nd Annual Meeting of the American Society of Hematology; Dec 4-7; Orlando, FL, USA 2010.
121. Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. [Letter]. 2013 Mar;13:819-20.
122. Struijk G.H., Minnee R.C., Koch S.D., et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010, 78:934-940. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
123. Vesikari T., Esposito S., Prymula R., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.